Centessa Pharmaceuticals PLC ADR (CNTA)

NASDAQ
Currency in USD
17.14
+0.27(+1.60%)
Closed
After Hours
17.140.00(0.00%)
CNTA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 11 days
Fair Value
Day's Range
16.2717.50
52 wk Range
7.7519.09
Key Statistics
Edit
Prev. Close
16.87
Open
16.5
Day's Range
16.27-17.5
52 wk Range
7.75-19.09
Volume
1.37M
Average Volume (3m)
801.33K
1-Year Change
59.44%
Book Value / Share
3.88
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CNTA Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
30.29
Upside
+76.70%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year
Show more

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Centessa Pharmaceuticals PLC ADR SWOT Analysis


Narcolepsy Breakthrough
Centessa's ORX750 poised to revolutionize $2B narcolepsy treatment market with potential for superior efficacy and once-daily dosing
Pipeline Diversity
Beyond narcolepsy, Centessa's SerpinPC shows promise in hemophilia treatment, demonstrating the company's multi-faceted approach to drug development
Market Momentum
CNTA stock surges 108% YTD, with analysts projecting further 50-100% growth potential pending crucial clinical data expected in late 2024
Financial Fortitude
Solid balance sheet with more cash than debt positions Centessa for continued R&D investment, while analyst targets range from $24 to $35
Read full SWOT analysis

Compare CNTA to Peers and Sector

Metrics to compare
CNTA
Peers
Sector
Relationship
P/E Ratio
−14.0x−2.2x−0.5x
PEG Ratio
−1.80−0.020.00
Price/Book
4.5x0.9x2.6x
Price / LTM Sales
329.8x10.3x3.0x
Upside (Analyst Target)
63.4%213.2%56.6%
Fair Value Upside
Unlock29.9%10.1%Unlock

Analyst Ratings

9 Buy
0 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 30.29
(+76.70% Upside)

Earnings

Latest Release
Nov 12, 2024
EPS / Forecast
-0.37 / -0.3963
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

FAQ

What Is the Centessa Pharmaceuticals (CNTA) Stock Price Today?

The Centessa Pharmaceuticals stock price today is 17.14.

What Stock Exchange Does Centessa Pharmaceuticals Trade On?

Centessa Pharmaceuticals is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Centessa Pharmaceuticals?

The stock symbol for Centessa Pharmaceuticals is "CNTA."

What Is the Centessa Pharmaceuticals Market Cap?

As of today, Centessa Pharmaceuticals market cap is 2.26B.

What is Centessa Pharmaceuticals Earnings Per Share?

The Centessa Pharmaceuticals EPS is -1.52.

What Is the Next Centessa Pharmaceuticals Earnings Date?

Centessa Pharmaceuticals will release its next earnings report on 26 Mar 2025.

From a Technical Analysis Perspective, Is CNTA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.